Abstract

We investigated the clinical significance of measuring serum CEA and CA19-9 levels for the early diagnosis of colorectal cancer in 157 cases. In the present study, the preoperative positive rate of serum CEA and CA19-9 levels in patients with curatively resected primary cancer was only 14.5% (11/76), 12.1% (4/33) of Dukes A, B, and 22.0% (11/50), 27.6% (8/29) of Dukes C, respectively, however, we found that serum CEA or CA19-9 levels were positive in 82.4% (14 cases) of 17 recurrent colorectal cancers after curative resection and that the elevation of these tumor markers was the first diagnostic method of recurrence in 38.1% of 21 cases. Thus, we conclude that the measurement of serum CEA and CA19-9 levels is not useful for the diagnosis of primary colorectal cancers, but is very useful for the early detection of recurrent colorectal cancers.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call